BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Summary

The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Timeline

Start

2009-11-19

Primary completion

2016-02-23

Completion

2016-02-23

Publications

• Background A. Patnaik et al. Supplementary materials /Supplementary methods. Annals of Oncology 2016
• Results Rowe EL. Automated drop volume apparatus for surface tension measurement. J Pharm Sci. 1972 May;61(5):781-2. doi: 10.1002/jps.2600610523. No abstract available.
• Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Pena C, Xia C, Reif S, Genvresse I, Ramanathan RK. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

Drugs

Indications